BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 22143997)

  • 1. Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalised anxiety disorder: an analysis of pooled data from three 8-week placebo-controlled studies.
    Stein DJ; Bandelow B; Merideth C; Olausson B; Szamosi J; Eriksson H
    Hum Psychopharmacol; 2011 Dec; 26(8):614-28. PubMed ID: 22143997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, double-blind study of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalized anxiety disorder.
    Khan A; Joyce M; Atkinson S; Eggens I; Baldytcheva I; Eriksson H
    J Clin Psychopharmacol; 2011 Aug; 31(4):418-28. PubMed ID: 21694613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Double-blind, randomized study of extended release quetiapine fumarate (quetiapine XR) monotherapy in older patients with generalized anxiety disorder.
    Mezhebovsky I; Mägi K; She F; Datto C; Eriksson H
    Int J Geriatr Psychiatry; 2013 Jun; 28(6):615-25. PubMed ID: 23070803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and tolerability of extended release quetiapine fumarate monotherapy in the acute treatment of generalized anxiety disorder: a randomized, placebo controlled and active-controlled study.
    Merideth C; Cutler AJ; She F; Eriksson H
    Int Clin Psychopharmacol; 2012 Jan; 27(1):40-54. PubMed ID: 22045039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extended release quetiapine fumarate (quetiapine XR) monotherapy as maintenance treatment for generalized anxiety disorder: a long-term, randomized, placebo-controlled trial.
    Katzman MA; Brawman-Mintzer O; Reyes EB; Olausson B; Liu S; Eriksson H
    Int Clin Psychopharmacol; 2011 Jan; 26(1):11-24. PubMed ID: 20881846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized, double-blind study of the efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in elderly patients with major depressive disorder.
    Katila H; Mezhebovsky I; Mulroy A; Berggren L; Eriksson H; Earley W; Datto C
    Am J Geriatr Psychiatry; 2013 Aug; 21(8):769-84. PubMed ID: 23567397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extended-release quetiapine as monotherapy for the treatment of adults with acute mania: a randomized, double-blind, 3-week trial.
    Cutler AJ; Datto C; Nordenhem A; Minkwitz M; Acevedo L; Darko D
    Clin Ther; 2011 Nov; 33(11):1643-58. PubMed ID: 22054797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of extended release quetiapine fumarate monotherapy in patients with major depressive disorder: a pooled analysis of two 6-week, double-blind, placebo-controlled studies.
    Weisler RH; Montgomery SA; Earley WR; Szamosi J; Lazarus A
    Int Clin Psychopharmacol; 2012 Jan; 27(1):27-39. PubMed ID: 22027845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extended release quetiapine fumarate in major depressive disorder: analysis in patients with anxious depression.
    Thase ME; Demyttenaere K; Earley WR; Gustafsson U; Udd M; Eriksson H
    Depress Anxiety; 2012 Jul; 29(7):574-86. PubMed ID: 22753280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of once-daily extended release quetiapine fumarate in patients with different levels of severity of generalized anxiety disorder.
    Montgomery SA; Locklear JC; Svedsäter H; Eriksson H
    Int Clin Psychopharmacol; 2014 Sep; 29(5):252-62. PubMed ID: 24394383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: a randomized, placebo-controlled trial.
    Liebowitz M; Lam RW; Lepola U; Datto C; Sweitzer D; Eriksson H
    Depress Anxiety; 2010 Oct; 27(10):964-76. PubMed ID: 20734365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study).
    Thase ME; Macfadden W; Weisler RH; Chang W; Paulsson B; Khan A; Calabrese JR;
    J Clin Psychopharmacol; 2006 Dec; 26(6):600-9. PubMed ID: 17110817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy and tolerability of once-daily extended release quetiapine fumarate in hospitalized patients with acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled study.
    Lindenmayer JP; Brown D; Liu S; Brecher M; Meulien D
    Psychopharmacol Bull; 2008; 41(3):11-35. PubMed ID: 18779774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study.
    Bandelow B; Chouinard G; Bobes J; Ahokas A; Eggens I; Liu S; Eriksson H
    Int J Neuropsychopharmacol; 2010 Apr; 13(3):305-20. PubMed ID: 19691907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A failed 6-week,randomized, double-blind, placebo-controlled study of once-daily extended release quetiapine fumarate in patients with acute schizophrenia: lessons learned.
    Cutler AJ; Tran-Johnson T; Kalali A; Aström M; Brecher M; Meulien D
    Psychopharmacol Bull; 2010; 43(4):37-69. PubMed ID: 21240151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of extended release quetiapine fumarate monotherapy in elderly patients with major depressive disorder: secondary analyses in subgroups of patients according to baseline anxiety, sleep disturbance, and pain levels.
    Montgomery SA; Altamura AC; Katila H; Datto C; Szamosi J; Eriksson H
    Int Clin Psychopharmacol; 2014 Mar; 29(2):93-105. PubMed ID: 24162081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Self-reported sedation profile of quetiapine extended-release and quetiapine immediate-release during 6-day initial dose escalation in bipolar depression: a multicenter, randomized, double-blind, phase IV study.
    Riesenberg RA; Baldytcheva I; Datto C
    Clin Ther; 2012 Nov; 34(11):2202-11. PubMed ID: 23059166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study.
    El-Khalili N; Joyce M; Atkinson S; Buynak RJ; Datto C; Lindgren P; Eriksson H
    Int J Neuropsychopharmacol; 2010 Aug; 13(7):917-32. PubMed ID: 20175941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extended release quetiapine fumarate as adjunct to antidepressant therapy in patients with major depressive disorder: pooled analyses of data in patients with anxious depression versus low levels of anxiety at baseline.
    Bandelow B; Bauer M; Vieta E; El-Khalili N; Gustafsson U; Earley WR; Eriksson H
    World J Biol Psychiatry; 2014 Feb; 15(2):155-66. PubMed ID: 24506289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term functioning and sleep quality in patients with major depressive disorder treated with extended-release quetiapine fumarate.
    Sheehan DV; Locklear J; Svedsäter H; Datto C
    Int Clin Psychopharmacol; 2012 Sep; 27(5):239-48. PubMed ID: 22859063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.